Amdocs Limited (NASDAQ:DOX) Shares Sold by Blue Trust Inc.

Blue Trust Inc. lowered its holdings in Amdocs Limited (NASDAQ:DOX) by 38.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,108 shares of the technology company’s stock after selling 692 shares during the period. Blue Trust Inc.’s holdings in Amdocs were worth $94,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in DOX. Pzena Investment Management LLC increased its position in shares of Amdocs by 12.3% in the third quarter. Pzena Investment Management LLC now owns 6,363,739 shares of the technology company’s stock worth $556,700,000 after acquiring an additional 696,136 shares in the last quarter. Hotchkis & Wiley Capital Management LLC increased its position in shares of Amdocs by 123.2% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 759,136 shares of the technology company’s stock worth $66,409,000 after acquiring an additional 419,045 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Amdocs by 1,207.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 271,701 shares of the technology company’s stock worth $23,768,000 after acquiring an additional 250,918 shares in the last quarter. Geode Capital Management LLC grew its holdings in Amdocs by 10.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,633,733 shares of the technology company’s stock valued at $143,498,000 after purchasing an additional 158,843 shares in the last quarter. Finally, Rice Hall James & Associates LLC grew its holdings in Amdocs by 338.3% during the 3rd quarter. Rice Hall James & Associates LLC now owns 167,023 shares of the technology company’s stock valued at $14,611,000 after purchasing an additional 128,919 shares in the last quarter. Institutional investors and hedge funds own 92.02% of the company’s stock.

Amdocs Trading Down 1.6 %

NASDAQ DOX opened at $87.91 on Friday. Amdocs Limited has a 12 month low of $74.41 and a 12 month high of $94.04. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.16 and a quick ratio of 1.20. The company has a market capitalization of $9.92 billion, a price-to-earnings ratio of 20.40, a price-to-earnings-growth ratio of 1.47 and a beta of 0.71. The company’s fifty day moving average price is $86.07 and its two-hundred day moving average price is $86.62.

Amdocs (NASDAQ:DOX) last posted its quarterly earnings data on Tuesday, February 4th. The technology company reported $1.45 EPS for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.19). Amdocs had a net margin of 10.19% and a return on equity of 18.89%. As a group, research analysts predict that Amdocs Limited will post 6.21 earnings per share for the current fiscal year.

Amdocs Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Sunday, April 20th. Stockholders of record on Monday, March 31st will be given a $0.527 dividend. This is an increase from Amdocs’s previous quarterly dividend of $0.48. This represents a $2.11 dividend on an annualized basis and a dividend yield of 2.40%. The ex-dividend date is Monday, March 31st. Amdocs’s dividend payout ratio (DPR) is presently 48.72%.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Barclays lowered their price target on shares of Amdocs from $113.00 to $111.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Oppenheimer raised their price target on shares of Amdocs from $98.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Finally, StockNews.com lowered shares of Amdocs from a “strong-buy” rating to a “buy” rating in a report on Wednesday. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $101.20.

Amdocs Profile

Amdocs Limited, through its subsidiaries, provides software and services worldwide. It designs, develops, operates, implements, supports, and markets open and modular cloud portfolio. The company provides CES23, a 5G and cloud-native microservices-based market-leading customer experience suite, that enables service providers to build, deliver, and monetize advanced services; Amdocs Subscription Marketplace, a software-as-a-service-based platform that includes an expansive network of pre-integrated digital services, such as media, gaming, eLearning, sports, and retail to security and business services; the monetization suite for charging, billing, policy, and revenue management; Intelligent networking suite with a set of modular, flexible, and open service lifecycle management capabilities for network automation journeys; amAIz, a telco GenAI framework; Amdocs Digital Brands Suite, a pre-integrated digital business suite; and Amdocs eSIM Cloud for service providers.